Skip to main content
SpringerLink
Log in

CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance: Response

  • Letter to the Editors
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cara-Fuentes G, Wei C, Segarra A, Ishimoto T, Rivard C, Johnson RJ, Reiser J, Garin EH (2013) CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance. Pediatr Nephrol. doi:10.1007/s00467-013-2679-1

    Google Scholar 

  2. Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW 3rd, Mundel P (2013) Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 369:2416–2423

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Segarra A, Jatem E, Quiles MT, Arbos MA, Ostos H, Valtierra N, Carnicer C, Agraz I, Salcedo MT (2014) Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome. Nefrologia 34:46–52

    PubMed  Google Scholar 

  4. Garin EH, Diaz LN, Mu W, Wasserfall C, Araya C, Segal M, Johnson RJ (2009) Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol 20:260–266

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

Jochen Reiser is an inventor with pending or issued patents on novel therapies in proteinuric kidney disease. He stands to gain royalties from their future commercialization.

Author information

Authors and Affiliations

  1. Division of Pediatric Nephrology, Department of Pediatrics, University of Florida, Gainesville, FL, USA

    Gabriel Cara-Fuentes & Eduardo H. Garin

  2. Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado, Denver, CO, USA

    Richard J. Johnson

  3. Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA

    Jochen Reiser

Authors
  1. Gabriel Cara-Fuentes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard J. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jochen Reiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eduardo H. Garin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eduardo H. Garin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cara-Fuentes, G., Johnson, R.J., Reiser, J. et al. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance: Response. Pediatr Nephrol 29, 1467–1468 (2014). https://doi.org/10.1007/s00467-014-2840-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-014-2840-5

Keywords

Search

Navigation